Anticancer therapy with checkpoint inhibitors: what, where and when?

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Protein kinases regulate DNA damage response, with CHK1 and CHK2 being key targets.
• Selective inhibitors for CHK1 and CHK2 are entering clinical trials for cancer treatment.

Purpose of the Study:

• To review recent preclinical data on the clinical applications of checkpoint kinase inhibitors.
• To elucidate the optimal timing and type of inhibitors for cancer therapy.
• To explore the distinct roles of CHK1 and CHK2 inhibition in combination therapies.

Main Methods:

• Analysis of cellular and in vivo preclinical models.
• Review of clinical trial data for checkpoint kinase inhibitors.
• Evaluation of combination strategies with DNA-damaging agents and targeted therapeutics.

Main Results:

• CHK1 inhibition enhances efficacy of DNA-damaging therapies.
• The clinical context for CHK2 inhibition is less defined, with distinct effects observed compared to CHK1.
• Both CHK1 and CHK2 inhibitors show potential when combined with other targeted therapies, such as PARP inhibitors.
• Single-agent activity of checkpoint kinase inhibitors is being investigated for specific genetic tumor backgrounds.

Conclusions:

• Checkpoint kinase inhibitors represent a promising therapeutic strategy in oncology.
• Further research is needed to define the precise roles and optimal combinations for CHK1 and CHK2 inhibitors.
• Understanding the genetic background of tumors is crucial for predicting response to single-agent checkpoint kinase inhibitors.